Variability	O
in	O
conditioned	B:C0002766
pain	I:C0002766
modulation	I:C0002766
predicts	O
response	O
to	O
NSAID	O
treatment	O
in	O
patients	O
with	O
knee	O
osteoarthritis	I:C0409959
.	O

Variability	O
in	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
predicts	O
response	O
to	O
NSAID	B:C3536840
treatment	O
in	O
patients	O
with	O
knee	O
osteoarthritis	I:C0409959
.	O

Variability	O
in	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
predicts	O
response	O
to	O
NSAID	O
treatment	B:C0087111
in	O
patients	O
with	O
knee	O
osteoarthritis	I:C0409959
.	O

Variability	O
in	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
predicts	O
response	O
to	O
NSAID	O
treatment	O
in	O
patients	O
with	O
knee	B:C0409959
osteoarthritis	I:C0409959
.	O

Patients	O
with	O
painful	B:C0030193
knee	O
osteoarthritis	I:C0409959
(	O
osteoarthritis	O
)	O
demonstrate	O
hyperalgesia	O
and	O
altered	O
pain	O
-	I:C0002766
modulatory	I:C0002766
responses	O
.	O

Patients	O
with	O
painful	O
knee	B:C0409959
osteoarthritis	I:C0409959
(	O
osteoarthritis	O
)	O
demonstrate	O
hyperalgesia	O
and	O
altered	O
pain	O
-	I:C0002766
modulatory	I:C0002766
responses	O
.	O

Patients	O
with	O
painful	O
knee	O
osteoarthritis	I:C0409959
(	O
osteoarthritis	B:C0409959
)	O
demonstrate	O
hyperalgesia	O
and	O
altered	O
pain	O
-	I:C0002766
modulatory	I:C0002766
responses	O
.	O

Patients	O
with	O
painful	O
knee	O
osteoarthritis	I:C0409959
(	O
osteoarthritis	O
)	O
demonstrate	O
hyperalgesia	B:C0020429
and	O
altered	O
pain	O
-	I:C0002766
modulatory	I:C0002766
responses	O
.	O

Patients	O
with	O
painful	O
knee	O
osteoarthritis	I:C0409959
(	O
osteoarthritis	O
)	O
demonstrate	O
hyperalgesia	O
and	O
altered	O
pain	B:C0002766
-	I:C0002766
modulatory	I:C0002766
responses	O
.	O

While	O
some	O
prior	O
work	O
has	O
demonstrated	O
cross-sectional	B:C0010362
associations	I:C0010362
between	O
laboratory	O
and	O
clinical	O
pain	O
measures	O
,	O
it	O
is	O
unknown	O
whether	O
individual	O
variability	O
in	O
quantitative	O
sensory	I:C0430838
testing	I:C0430838
(	O
quantitative	O
sensory	I:C0430838
testing	I:C0430838
)	O
responses	O
at	O
baseline	O
can	O
prospectively	O
predict	O
analgesic	O
treatment	O
responses	I:C0521982
.	O

While	O
some	O
prior	O
work	O
has	O
demonstrated	O
cross-sectional	O
associations	I:C0010362
between	O
laboratory	B:C0022877
and	O
clinical	O
pain	O
measures	O
,	O
it	O
is	O
unknown	O
whether	O
individual	O
variability	O
in	O
quantitative	O
sensory	I:C0430838
testing	I:C0430838
(	O
quantitative	O
sensory	I:C0430838
testing	I:C0430838
)	O
responses	O
at	O
baseline	O
can	O
prospectively	O
predict	O
analgesic	O
treatment	O
responses	I:C0521982
.	O

While	O
some	O
prior	O
work	O
has	O
demonstrated	O
cross-sectional	O
associations	I:C0010362
between	O
laboratory	O
and	O
clinical	O
pain	O
measures	O
,	O
it	O
is	O
unknown	O
whether	O
individual	O
variability	O
in	O
quantitative	B:C0430838
sensory	I:C0430838
testing	I:C0430838
(	O
quantitative	O
sensory	I:C0430838
testing	I:C0430838
)	O
responses	O
at	O
baseline	O
can	O
prospectively	O
predict	O
analgesic	O
treatment	O
responses	I:C0521982
.	O

While	O
some	O
prior	O
work	O
has	O
demonstrated	O
cross-sectional	O
associations	I:C0010362
between	O
laboratory	O
and	O
clinical	O
pain	O
measures	O
,	O
it	O
is	O
unknown	O
whether	O
individual	O
variability	O
in	O
quantitative	O
sensory	I:C0430838
testing	I:C0430838
(	O
quantitative	B:C0430838
sensory	I:C0430838
testing	I:C0430838
)	O
responses	O
at	O
baseline	O
can	O
prospectively	O
predict	O
analgesic	O
treatment	O
responses	I:C0521982
.	O

While	O
some	O
prior	O
work	O
has	O
demonstrated	O
cross-sectional	O
associations	I:C0010362
between	O
laboratory	O
and	O
clinical	O
pain	O
measures	O
,	O
it	O
is	O
unknown	O
whether	O
individual	O
variability	O
in	O
quantitative	O
sensory	I:C0430838
testing	I:C0430838
(	O
quantitative	O
sensory	I:C0430838
testing	I:C0430838
)	O
responses	O
at	O
baseline	O
can	O
prospectively	O
predict	O
analgesic	B:C0002771
treatment	O
responses	I:C0521982
.	O

While	O
some	O
prior	O
work	O
has	O
demonstrated	O
cross-sectional	O
associations	I:C0010362
between	O
laboratory	O
and	O
clinical	O
pain	O
measures	O
,	O
it	O
is	O
unknown	O
whether	O
individual	O
variability	O
in	O
quantitative	O
sensory	I:C0430838
testing	I:C0430838
(	O
quantitative	O
sensory	I:C0430838
testing	I:C0430838
)	O
responses	O
at	O
baseline	O
can	O
prospectively	O
predict	O
analgesic	O
treatment	B:C0521982
responses	I:C0521982
.	O

Patients	O
with	O
knee	B:C0409959
OA	I:C0409959
(	O
n	O
=	O
35	O
)	O
were	O
compared	O
on	O
quantitative	O
sensory	I:C0430838
testing	I:C0430838
responses	O
to	O
a	O
demographically	O
-	O
matched	O
pain	O
-	O
free	O
control	O
group	O
(	O
n	O
=	O
39	O
)	O
,	O
after	O
which	O
patients	O
completed	O
a	O
month	O
-	O
long	O
treatment	O
study	I:C3161471
of	O
diclofenac	O
sodium	O
topical	O
gel	O
(	O
1	O
%	O
)	O
,	O
applied	O
up	O
to	O
4	O
times	O
daily	O
.	O

Patients	O
with	O
knee	O
OA	I:C0409959
(	O
n	O
=	O
35	O
)	O
were	O
compared	O
on	O
quantitative	B:C0430838
sensory	I:C0430838
testing	I:C0430838
responses	O
to	O
a	O
demographically	O
-	O
matched	O
pain	O
-	O
free	O
control	O
group	O
(	O
n	O
=	O
39	O
)	O
,	O
after	O
which	O
patients	O
completed	O
a	O
month	O
-	O
long	O
treatment	O
study	I:C3161471
of	O
diclofenac	O
sodium	O
topical	O
gel	O
(	O
1	O
%	O
)	O
,	O
applied	O
up	O
to	O
4	O
times	O
daily	O
.	O

Patients	O
with	O
knee	O
OA	I:C0409959
(	O
n	O
=	O
35	O
)	O
were	O
compared	O
on	O
quantitative	O
sensory	I:C0430838
testing	I:C0430838
responses	O
to	O
a	O
demographically	O
-	O
matched	O
pain	O
-	O
free	O
control	O
group	O
(	O
n	O
=	O
39	O
)	O
,	O
after	O
which	O
patients	O
completed	O
a	O
month	O
-	O
long	O
treatment	B:C3161471
study	I:C3161471
of	O
diclofenac	O
sodium	O
topical	O
gel	O
(	O
1	O
%	O
)	O
,	O
applied	O
up	O
to	O
4	O
times	O
daily	O
.	O

osteoarthritis	B:C0409959
patients	O
demonstrated	O
reduced	O
pain	O
thresholds	I:C0162703
at	O
multiple	O
anatomic	O
sites	I:C1515974
,	O
as	O
well	O
as	O
reduced	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
(	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
)	O
and	O
enhanced	O
temporal	O
summation	I:C0234110
of	O
pain	O
.	O

osteoarthritis	O
patients	O
demonstrated	O
reduced	O
pain	B:C0162703
thresholds	I:C0162703
at	O
multiple	O
anatomic	O
sites	I:C1515974
,	O
as	O
well	O
as	O
reduced	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
(	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
)	O
and	O
enhanced	O
temporal	O
summation	I:C0234110
of	O
pain	O
.	O

osteoarthritis	O
patients	O
demonstrated	O
reduced	O
pain	O
thresholds	I:C0162703
at	O
multiple	O
anatomic	B:C1515974
sites	I:C1515974
,	O
as	O
well	O
as	O
reduced	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
(	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
)	O
and	O
enhanced	O
temporal	O
summation	I:C0234110
of	O
pain	O
.	O

osteoarthritis	O
patients	O
demonstrated	O
reduced	O
pain	O
thresholds	I:C0162703
at	O
multiple	O
anatomic	O
sites	I:C1515974
,	O
as	O
well	O
as	O
reduced	O
conditioned	B:C0002766
pain	I:C0002766
modulation	I:C0002766
(	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
)	O
and	O
enhanced	O
temporal	O
summation	I:C0234110
of	O
pain	O
.	O

osteoarthritis	O
patients	O
demonstrated	O
reduced	O
pain	O
thresholds	I:C0162703
at	O
multiple	O
anatomic	O
sites	I:C1515974
,	O
as	O
well	O
as	O
reduced	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
(	O
conditioned	B:C0002766
pain	I:C0002766
modulation	I:C0002766
)	O
and	O
enhanced	O
temporal	O
summation	I:C0234110
of	O
pain	O
.	O

osteoarthritis	O
patients	O
demonstrated	O
reduced	O
pain	O
thresholds	I:C0162703
at	O
multiple	O
anatomic	O
sites	I:C1515974
,	O
as	O
well	O
as	O
reduced	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
(	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
)	O
and	O
enhanced	O
temporal	B:C0234110
summation	I:C0234110
of	O
pain	O
.	O

osteoarthritis	O
patients	O
demonstrated	O
reduced	O
pain	O
thresholds	I:C0162703
at	O
multiple	O
anatomic	O
sites	I:C1515974
,	O
as	O
well	O
as	O
reduced	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
(	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
)	O
and	O
enhanced	O
temporal	O
summation	I:C0234110
of	O
pain	B:C0030193
.	O

The	O
most	O
pain	B:C0162703
-	I:C0162703
sensitive	I:C0162703
patients	O
tended	O
to	O
report	O
the	O
most	O
intense	O
and	O
neuropathic	O
osteoarthritis	O
pain	O
.	O

The	O
most	O
pain	O
-	I:C0162703
sensitive	I:C0162703
patients	O
tended	O
to	O
report	O
the	O
most	O
intense	O
and	O
neuropathic	B:C3714625
osteoarthritis	O
pain	O
.	O

The	O
most	O
pain	O
-	I:C0162703
sensitive	I:C0162703
patients	O
tended	O
to	O
report	O
the	O
most	O
intense	O
and	O
neuropathic	O
osteoarthritis	B:C0409959
pain	O
.	O

The	O
most	O
pain	O
-	I:C0162703
sensitive	I:C0162703
patients	O
tended	O
to	O
report	O
the	O
most	O
intense	O
and	O
neuropathic	O
osteoarthritis	O
pain	B:C0030193
.	O

Following	O
diclofenac	B:C0012091
treatment	O
,	O
the	O
knee	O
OA	I:C0409959
cohort	O
showed	O
a	O
roughly	O
30	O
%	O
improvement	O
in	O
pain	O
,	O
regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
neuropathic	O
symptoms	I:C3714625
.	O

Following	O
diclofenac	O
treatment	B:C0087111
,	O
the	O
knee	O
OA	I:C0409959
cohort	O
showed	O
a	O
roughly	O
30	O
%	O
improvement	O
in	O
pain	O
,	O
regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
neuropathic	O
symptoms	I:C3714625
.	O

Following	O
diclofenac	O
treatment	O
,	O
the	O
knee	B:C0409959
OA	I:C0409959
cohort	O
showed	O
a	O
roughly	O
30	O
%	O
improvement	O
in	O
pain	O
,	O
regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
neuropathic	O
symptoms	I:C3714625
.	O

Following	O
diclofenac	O
treatment	O
,	O
the	O
knee	O
OA	I:C0409959
cohort	B:C0599755
showed	O
a	O
roughly	O
30	O
%	O
improvement	O
in	O
pain	O
,	O
regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
neuropathic	O
symptoms	I:C3714625
.	O

Following	O
diclofenac	O
treatment	O
,	O
the	O
knee	O
OA	I:C0409959
cohort	O
showed	O
a	O
roughly	O
30	O
%	O
improvement	O
in	O
pain	B:C0030193
,	O
regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
neuropathic	O
symptoms	I:C3714625
.	O

Following	O
diclofenac	O
treatment	O
,	O
the	O
knee	O
OA	I:C0409959
cohort	O
showed	O
a	O
roughly	O
30	O
%	O
improvement	O
in	O
pain	O
,	O
regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
neuropathic	B:C3714625
symptoms	I:C3714625
.	O

Baseline	O
conditioned	B:C0002766
pain	I:C0002766
modulation	I:C0002766
scores	O
,	O
an	O
index	O
of	O
endogenous	O
pain	O
-	I:C3895972
inhibitory	I:C3895972
capacity	I:C3895972
,	O
were	O
prospectively	O
associated	O
with	O
treatment	O
-	O
related	O
changes	O
in	O
clinical	O
pain	O
.	O

Baseline	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
scores	O
,	O
an	O
index	O
of	O
endogenous	O
pain	B:C3895972
-	I:C3895972
inhibitory	I:C3895972
capacity	I:C3895972
,	O
were	O
prospectively	O
associated	O
with	O
treatment	O
-	O
related	O
changes	O
in	O
clinical	O
pain	O
.	O

Baseline	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
scores	O
,	O
an	O
index	O
of	O
endogenous	O
pain	O
-	I:C3895972
inhibitory	I:C3895972
capacity	I:C3895972
,	O
were	O
prospectively	O
associated	O
with	O
treatment	B:C0087111
-	O
related	O
changes	O
in	O
clinical	O
pain	O
.	O

Baseline	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
scores	O
,	O
an	O
index	O
of	O
endogenous	O
pain	O
-	I:C3895972
inhibitory	I:C3895972
capacity	I:C3895972
,	O
were	O
prospectively	O
associated	O
with	O
treatment	O
-	O
related	O
changes	O
in	O
clinical	O
pain	B:C0030193
.	O

Specifically	O
,	O
participants	B:C0679646
with	O
higher	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
at	O
baseline	O
(	O
i.e.	O
,	O
better	O
functioning	O
endogenous	O
pain	O
-	O
inhibitory	O
systems	I:C0574031
)	O
showed	O
more	O
reduction	O
in	O
pain	O
at	O
the	O
end	O
of	O
treatment	O
(	O
p	O
<	O
.05	O
)	O
.	O

Specifically	O
,	O
participants	O
with	O
higher	O
conditioned	B:C0002766
pain	I:C0002766
modulation	I:C0002766
at	O
baseline	O
(	O
i.e.	O
,	O
better	O
functioning	O
endogenous	O
pain	O
-	O
inhibitory	O
systems	I:C0574031
)	O
showed	O
more	O
reduction	O
in	O
pain	O
at	O
the	O
end	O
of	O
treatment	O
(	O
p	O
<	O
.05	O
)	O
.	O

Specifically	O
,	O
participants	O
with	O
higher	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
at	O
baseline	O
(	O
i.e.	O
,	O
better	O
functioning	O
endogenous	O
pain	B:C0030193
-	O
inhibitory	O
systems	I:C0574031
)	O
showed	O
more	O
reduction	O
in	O
pain	O
at	O
the	O
end	O
of	O
treatment	O
(	O
p	O
<	O
.05	O
)	O
.	O

Specifically	O
,	O
participants	O
with	O
higher	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
at	O
baseline	O
(	O
i.e.	O
,	O
better	O
functioning	O
endogenous	O
pain	O
-	O
inhibitory	B:C0574031
systems	I:C0574031
)	O
showed	O
more	O
reduction	O
in	O
pain	O
at	O
the	O
end	O
of	O
treatment	O
(	O
p	O
<	O
.05	O
)	O
.	O

Specifically	O
,	O
participants	O
with	O
higher	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
at	O
baseline	O
(	O
i.e.	O
,	O
better	O
functioning	O
endogenous	O
pain	O
-	O
inhibitory	O
systems	I:C0574031
)	O
showed	O
more	O
reduction	B:C0441610
in	O
pain	O
at	O
the	O
end	O
of	O
treatment	O
(	O
p	O
<	O
.05	O
)	O
.	O

Specifically	O
,	O
participants	O
with	O
higher	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
at	O
baseline	O
(	O
i.e.	O
,	O
better	O
functioning	O
endogenous	O
pain	O
-	O
inhibitory	O
systems	I:C0574031
)	O
showed	O
more	O
reduction	O
in	O
pain	B:C0030193
at	O
the	O
end	O
of	O
treatment	O
(	O
p	O
<	O
.05	O
)	O
.	O

Specifically	O
,	O
participants	O
with	O
higher	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
at	O
baseline	O
(	O
i.e.	O
,	O
better	O
functioning	O
endogenous	O
pain	O
-	O
inhibitory	O
systems	I:C0574031
)	O
showed	O
more	O
reduction	O
in	O
pain	O
at	O
the	O
end	O
of	O
treatment	B:C0087111
(	O
p	O
<	O
.05	O
)	O
.	O

These	O
results	B:C0456984
support	O
prior	O
findings	O
of	O
amplified	O
pain	I:C0162703
sensitivity	I:C0162703
and	O
reduced	O
pain	O
-	I:C3895972
inhibition	I:C3895972
in	O
osteoarthritis	O
patients	O
.	O

These	O
results	O
support	O
prior	O
findings	B:C0243095
of	O
amplified	O
pain	I:C0162703
sensitivity	I:C0162703
and	O
reduced	O
pain	O
-	I:C3895972
inhibition	I:C3895972
in	O
osteoarthritis	O
patients	O
.	O

These	O
results	O
support	O
prior	O
findings	O
of	O
amplified	B:C0162703
pain	I:C0162703
sensitivity	I:C0162703
and	O
reduced	O
pain	O
-	I:C3895972
inhibition	I:C3895972
in	O
osteoarthritis	O
patients	O
.	O

These	O
results	O
support	O
prior	O
findings	O
of	O
amplified	O
pain	I:C0162703
sensitivity	I:C0162703
and	O
reduced	O
pain	B:C3895972
-	I:C3895972
inhibition	I:C3895972
in	O
osteoarthritis	O
patients	O
.	O

These	O
results	O
support	O
prior	O
findings	O
of	O
amplified	O
pain	I:C0162703
sensitivity	I:C0162703
and	O
reduced	O
pain	O
-	I:C3895972
inhibition	I:C3895972
in	O
osteoarthritis	B:C0409959
patients	O
.	O

Moreover	O
,	O
the	O
moderate	O
to	O
strong	O
associations	O
between	O
laboratory	B:C0022877
-	I:C0022877
based	I:C0022877
measures	O
of	O
pain	O
sensitivity	I:C0162703
and	O
indices	O
of	O
clinical	O
pain	O
highlight	O
the	O
clinical	O
relevance	O
of	O
quantitative	O
sensory	I:C0430838
testing	I:C0430838
in	O
this	O
sample	O
.	O

Moreover	O
,	O
the	O
moderate	O
to	O
strong	O
associations	O
between	O
laboratory	O
-	I:C0022877
based	I:C0022877
measures	O
of	O
pain	B:C0162703
sensitivity	I:C0162703
and	O
indices	O
of	O
clinical	O
pain	O
highlight	O
the	O
clinical	O
relevance	O
of	O
quantitative	O
sensory	I:C0430838
testing	I:C0430838
in	O
this	O
sample	O
.	O

Moreover	O
,	O
the	O
moderate	O
to	O
strong	O
associations	O
between	O
laboratory	O
-	I:C0022877
based	I:C0022877
measures	O
of	O
pain	O
sensitivity	I:C0162703
and	O
indices	O
of	O
clinical	O
pain	B:C0030193
highlight	O
the	O
clinical	O
relevance	O
of	O
quantitative	O
sensory	I:C0430838
testing	I:C0430838
in	O
this	O
sample	O
.	O

Moreover	O
,	O
the	O
moderate	O
to	O
strong	O
associations	O
between	O
laboratory	O
-	I:C0022877
based	I:C0022877
measures	O
of	O
pain	O
sensitivity	I:C0162703
and	O
indices	O
of	O
clinical	O
pain	O
highlight	O
the	O
clinical	O
relevance	O
of	O
quantitative	B:C0430838
sensory	I:C0430838
testing	I:C0430838
in	O
this	O
sample	O
.	O

Finally	O
,	O
the	O
prospective	O
association	O
between	O
conditioned	B:C0002766
pain	I:C0002766
modulation	I:C0002766
and	O
diclofenac	O
response	O
suggests	O
that	O
QST	O
-	I:C0430838
based	I:C0430838
phenotyping	O
may	O
have	O
utility	O
in	O
explaining	O
inter-	O
patient	O
variability	O
in	O
long	O
-	O
term	O
analgesic	O
treatment	O
outcomes	O
.	O

Finally	O
,	O
the	O
prospective	O
association	O
between	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
and	O
diclofenac	B:C0012091
response	O
suggests	O
that	O
QST	O
-	I:C0430838
based	I:C0430838
phenotyping	O
may	O
have	O
utility	O
in	O
explaining	O
inter-	O
patient	O
variability	O
in	O
long	O
-	O
term	O
analgesic	O
treatment	O
outcomes	O
.	O

Finally	O
,	O
the	O
prospective	O
association	O
between	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
and	O
diclofenac	O
response	O
suggests	O
that	O
QST	B:C0430838
-	I:C0430838
based	I:C0430838
phenotyping	O
may	O
have	O
utility	O
in	O
explaining	O
inter-	O
patient	O
variability	O
in	O
long	O
-	O
term	O
analgesic	O
treatment	O
outcomes	O
.	O

Finally	O
,	O
the	O
prospective	O
association	O
between	O
conditioned	O
pain	I:C0002766
modulation	I:C0002766
and	O
diclofenac	O
response	O
suggests	O
that	O
QST	O
-	I:C0430838
based	I:C0430838
phenotyping	O
may	O
have	O
utility	O
in	O
explaining	O
inter-	O
patient	O
variability	O
in	O
long	O
-	O
term	O
analgesic	B:C0002771
treatment	O
outcomes	O
.	O

ClinicalTrials	B:C0008976
.	O
Gov	O
Identifier	O
:	O
NCT01383954	O
.	O

